<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39309487</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2211-3835</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Acta pharmaceutica Sinica. B</Title><ISOAbbreviation>Acta Pharm Sin B</ISOAbbreviation></Journal><ArticleTitle>Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics.</ArticleTitle><Pagination><StartPage>4028</StartPage><EndPage>4044</EndPage><MedlinePgn>4028-4044</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.apsb.2024.05.026</ELocationID><Abstract><AbstractText>There are only eight approved small molecule antiviral drugs for treating COVID-19. Among them, four are nucleotide analogues (remdesivir, JT001, molnupiravir, and azvudine), while the other four are protease inhibitors (nirmatrelvir, ensitrelvir, leritrelvir, and simnotrelvir-ritonavir). Antiviral resistance, unfavourable drug‒drug interaction, and toxicity have been reported in previous studies. Thus there is a dearth of new treatment options for SARS-CoV-2. In this work, a three-tier cell-based screening was employed to identify novel compounds with anti-SARS-CoV-2 activity. One compound, designated <b>172</b>, demonstrated broad-spectrum antiviral activity against multiple human pathogenic coronaviruses and different SARS-CoV-2 variants of concern. Mechanistic studies validated by reverse genetics showed that compound <b>172</b> inhibits the 3-chymotrypsin-like protease (3CLpro) by binding to an allosteric site and reduces 3CLpro dimerization. A drug synergistic checkerboard assay demonstrated that compound <b>172</b> can achieve drug synergy with nirmatrelvir <i>in vitro</i>. <i>In vivo</i> studies confirmed the antiviral activity of compound <b>172</b> in both Golden Syrian Hamsters and K18 humanized ACE2 mice. Overall, this study identified an alternative druggable site on the SARS-CoV-2 3CLpro, proposed a potential combination therapy with nirmatrelvir to reduce the risk of antiviral resistance and shed light on the development of allosteric protease inhibitors for treating a range of coronavirus diseases.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Chris Chun-Yiu</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Jasper Fuk-Woo</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, the University of Hong Kong-Shenzhen Hospital, Shenzhen 518000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academician Workstation of Hainan Province, Hainan Medical University-the University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Haikou 571100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Kaiming</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jian-Piao</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chik</LastName><ForeName>Kenn Ka-Heng</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yixin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Chon Phin</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Allen Wing-Ho</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Wan-Mui</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ip</LastName><ForeName>Jonathan Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsang</LastName><ForeName>Jessica Oi-Ling</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tong-Yun</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yubin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Zhenzhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Jianli</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Zi-Wei</ForeName><Initials>ZW</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Hin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, the University of Hong Kong-Shenzhen Hospital, Shenzhen 518000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>To</LastName><ForeName>Kelvin Kai-Wang</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, the University of Hong Kong-Shenzhen Hospital, Shenzhen 518000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Xing-Yi</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>College of Biology, Hunan Provincial Key Laboratory of Medical Virology, Hunan University, Changsha 410082, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Dong-Yan</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuen</LastName><ForeName>Kwok-Yung</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, the University of Hong Kong-Shenzhen Hospital, Shenzhen 518000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academician Workstation of Hainan Province, Hainan Medical University-the University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Haikou 571100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shuofeng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, the University of Hong Kong-Shenzhen Hospital, Shenzhen 518000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong SAR 999077, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Acta Pharm Sin B</MedlineTA><NlmUniqueID>101600560</NlmUniqueID><ISSNLinking>2211-3835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3CLpro inhibitor</Keyword><Keyword MajorTopicYN="N">Allosteric-site inhibitor</Keyword><Keyword MajorTopicYN="N">Animal models</Keyword><Keyword MajorTopicYN="N">Broad-spectrum antiviral treatment</Keyword><Keyword MajorTopicYN="N">Chemical genetics</Keyword><Keyword MajorTopicYN="N">High throughput screening</Keyword><Keyword MajorTopicYN="N">Reverse genetics</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors have no conflict to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39309487</ArticleId><ArticleId IdType="pmc">PMC11413674</ArticleId><ArticleId IdType="doi">10.1016/j.apsb.2024.05.026</ArticleId><ArticleId IdType="pii">S2211-3835(24)00219-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112372</ArticleId><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820.</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159286</ArticleId><ArticleId IdType="pubmed">31986261</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., Valdes A.M., Polidori L., Antonelli M., Penamakuri S., Nogal A., et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399:1618–1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368:409–412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen D.R., Allerton C.M.N., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368:779–782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164392</ArticleId><ArticleId IdType="pubmed">32277040</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Iketani S., Guo Y., Chan J.F.W., Wang M., Liu L., et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602:676–681.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Tchesnokov E.P., Woolner E., Perry J.K., Feng J.Y., Porter D.P., et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295:6785–6797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242698</ArticleId><ArticleId IdType="pubmed">32284326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Tchesnokov E.P., Schinazi R.F., Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021;297</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8110631</ArticleId><ArticleId IdType="pubmed">33989635</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukae H., Yotsuyanagi H., Ohmagari N., Doi Y., Sakaguchi H., Sonoyama T., et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study. Clin Infect Dis. 2022;76:1403–1411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10110269</ArticleId><ArticleId IdType="pubmed">36477182</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., et al. Remdesivir for the treatment of Covid-19―final report. N Engl J Med. 2020;383:1813–1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Yin W., Zhang Y., Shang W., Wang Z., Luan X., et al. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. 2021;31:1212–1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8477624</ArticleId><ArticleId IdType="pubmed">34584244</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.L., Li Y.H., Wang L.L., Liu H.Q., Lu S.Y., Liu Y., et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther. 2021;6:414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646019</ArticleId><ArticleId IdType="pubmed">34873151</ArticleId></ArticleIdList></Reference><Reference><Citation>Merches K., Breunig L., Fender J., Brand T., Batz V., Idel S., et al. The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro. Arch Toxicol. 2022;96:2341–2360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110936</ArticleId><ArticleId IdType="pubmed">35579693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S., Hill C.S., Sarkar S., Tse L.V., Woodburn B.M.D., Schinazi R.F., et al. Beta-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis. 2021;224:415–419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8136050</ArticleId><ArticleId IdType="pubmed">33961695</ArticleId></ArticleIdList></Reference><Reference><Citation>Unoh Y., Uehara S., Nakahara K., Nobori H., Yamatsu Y., Yamamoto S., et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem. 2022;65:6499–6512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8982737</ArticleId><ArticleId IdType="pubmed">35352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y., Lin Z., Liang J., Sun R., Li Y., Lin B., et al. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial. EClinicalMedicine. 2024;67</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10770433</ArticleId><ArticleId IdType="pubmed">38188690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Xiao W., Tang Y., Cao M., Shu D., Asakawa T., et al. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial. Lancet Reg Health West Pac. 2023;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10362366</ArticleId><ArticleId IdType="pubmed">37484496</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Lewandowski E.M., Tan H., Zhang X., Morgan R.T., Zhang X., et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. ACS Cent Sci. 2023;9:1658–1669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10451032</ArticleId><ArticleId IdType="pubmed">37637734</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens L.J., Pruijssers A.J., Lee H.W., Gordon C.J., Tchesnokov E.P., Gribble J., et al. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci Transl Med. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9097878</ArticleId><ArticleId IdType="pubmed">35482820</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S., Mohri H., Culbertson B., Hong S.J., Duan Y., Luck M.I., et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023;613:558–564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9849135</ArticleId><ArticleId IdType="pubmed">36351451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiso M., Furusawa Y., Uraki R., Imai M., Yamayoshi S., Kawaoka Y. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. Nat Commun. 2023;14:3952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10319741</ArticleId><ArticleId IdType="pubmed">37402789</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H., Kim J.Y., Chang Y.T., Nam H.G. Forward chemical genetic screening. Methods Mol Biol. 2014;1062:393–404.</Citation><ArticleIdList><ArticleId IdType="pubmed">24057378</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong F., Cheung A.K., Huang S.M. Chemical genetics-based target identification in drug discovery. Annu Rev Pharmacol Toxicol. 2012;52:57–78.</Citation><ArticleIdList><ArticleId IdType="pubmed">21819237</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Fang C., Zhang Q., Zhang R., Zhao X., Duan Y., et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell. 2022;13:689–693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8533666</ArticleId><ArticleId IdType="pubmed">34687004</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Yin X., Meng X., Chan J.F., Ye Z.W., Riva L., et al. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature. 2021;593:418–423.</Citation><ArticleIdList><ArticleId IdType="pubmed">33727703</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Chu H., Huang J., Zhao X., Ye Z.W., Lai P.M., et al. Viruses harness YxxØ motif to interact with host AP2M1 for replication: a vulnerable broad-spectrum antiviral target. Sci Adv. 2020;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455044</ArticleId><ArticleId IdType="pubmed">32923629</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewandowski K., Xu Y., Pullan S.T., Lumley S.F., Foster D., Sanderson N., et al. Metagenomic nanopore sequencing of influenza virus direct from clinical respiratory samples. J Clin Microbiol. 2019;58</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6935926</ArticleId><ArticleId IdType="pubmed">31666364</ArticleId></ArticleIdList></Reference><Reference><Citation>Artic network-nCoV 2019 sequencing protocol. Available from: https://artic.network/ncov-2019 (Accessed 26/3).</Citation></Reference><Reference><Citation>Liang R., Ye Z.W., Ong C.P., Qin Z., Xie Y., Fan Y., et al. The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage. Emerg Microbes Infect. 2022;11:2093–2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9448440</ArticleId><ArticleId IdType="pubmed">35943779</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Chu H., Chan J.F., Ye Z.W., Wen L., Yan B., et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nat Commun. 2019;10:120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6328544</ArticleId><ArticleId IdType="pubmed">30631056</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland R.A. John Wiley &amp; Sons; 2013. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists.</Citation><ArticleIdList><ArticleId IdType="pubmed">16350889</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Chen J., Cheng T., Gindulyte A., He J., He S., et al. PubChem 2023 update. Nucleic Acids Res. 2023;51:D1373–D1380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9825602</ArticleId><ArticleId IdType="pubmed">36305812</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., et al. The protein data bank. Nucleic Acids Res. 2000;28:235–242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102472</ArticleId><ArticleId IdType="pubmed">10592235</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon J.C., Myers J.B., Folta T., Shoja V., Heath L.S., Onufriev A. H++: a server for estimating pKa s and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005;33:W368–W371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160225</ArticleId><ArticleId IdType="pubmed">15980491</ArticleId></ArticleIdList></Reference><Reference><Citation>MetaPocket: a meta approach to improve protein ligand binding site prediction. OMICS. 2009;13:325–330.</Citation><ArticleIdList><ArticleId IdType="pubmed">19645590</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroganov O.V., Novikov F.N., Stroylov V.S., Kulkov V., Chilov G.G. Lead finder: an approach to improve accuracy of protein‒ligand docking, binding energy estimation, and virtual screening. J Chem Inf Model. 2008;48:2371–2385.</Citation><ArticleIdList><ArticleId IdType="pubmed">19007114</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier J.A., Martinez C., Kasavajhala K., Wickstrom L., Hauser K.E., Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11:3696–3713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821407</ArticleId><ArticleId IdType="pubmed">26574453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Wolf R.M., Caldwell J.W., Kollman P.A., Case D.A. Development and testing of a general amber force field. J Comput Chem. 2004;25:1157–1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">15116359</ArticleId></ArticleIdList></Reference><Reference><Citation>Case D.A., Cheatham T.E., 3rd, Darden T., Gohlke H., Luo R., Merz K.M., Jr., et al. The amber biomolecular simulation programs. J Comput Chem. 2005;26:1668–1688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1989667</ArticleId><ArticleId IdType="pubmed">16200636</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura N., Kudoh S., Kimura T., Mitsuoka S., Matsuura K., Hirata K., et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer. 2006;51:363–368.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364494</ArticleId></ArticleIdList></Reference><Reference><Citation>Günther S., Reinke P.Y.A., Fernández-García Y., Lieske J., Lane T.J., Ginn H.M., et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science. 2021;372:642–646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8224385</ArticleId><ArticleId IdType="pubmed">33811162</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F., Kok K.H., Zhu Z., Chu H., To K.K., Yuan S., et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221–236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067204</ArticleId><ArticleId IdType="pubmed">31987001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman R.L., Kania R.S., Brothers M.A., Davies J.F., Ferre R.A., Gajiwala K.S., et al. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J Med Chem. 2020;63:12725–12747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571312</ArticleId><ArticleId IdType="pubmed">33054210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbalenya A.E., Donchenko A.P., Blinov V.M., Koonin E.V. Cysteine proteases of positive strand RNA viruses and chymotrypsin-like serine proteases: a distinct protein superfamily with a common structural fold. FEBS Lett. 1989;243:103–114.</Citation><ArticleIdList><ArticleId IdType="pubmed">2645167</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C.Y., Chang H.C., Hsu W.C., Lin T.Z., Lin C.H., Chang G.G. Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry. 2004;43:14958–14970.</Citation><ArticleIdList><ArticleId IdType="pubmed">15554703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu W.C., Chang H.C., Chou C.Y., Tsai P.J., Lin P.I., Chang G.G. Critical assessment of important regions in the subunit association and catalytic action of the severe acute respiratory syndrome coronavirus main protease. J Biol Chem. 2005;280:22741–22748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8060872</ArticleId><ArticleId IdType="pubmed">15831489</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., Verschueren K.H., Anand K., Shen J., Yang M., Xu Y., et al. pH-dependent conformational flexibility of the SARS-CoV main proteinase (Mpro) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J Mol Biol. 2005;354:25–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094468</ArticleId><ArticleId IdType="pubmed">16242152</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Sivaraman J., Song J. Mechanism for controlling the dimer-monomer switch and coupling dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease. J Virol. 2008;82:4620–4629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2293028</ArticleId><ArticleId IdType="pubmed">18305031</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson I., Sääf A., Whitley P., Gafvelin G., Waller C., von Heijne G. Proline-induced disruption of a transmembrane alpha-helix in its natural environment. J Mol Biol. 1998;284:1165–1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">9837734</ArticleId></ArticleIdList></Reference><Reference><Citation>Noske G.D., Song Y., Fernandes R.S., Chalk R., Elmassoudi H., Koekemoer L., et al. An in-solution snapshot of SARS-CoV-2 main protease maturation process and inhibition. Nat Commun. 2023;14:1545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10027274</ArticleId><ArticleId IdType="pubmed">36941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira G.M., Kronenberger T., Tonduru A.K., Hirata R.D.C., Hirata M.H., Poso A. SARS-CoV-2 Mpro conformational changes induced by covalently bound ligands. J Biomol Struct Dyn. 2022;40:12347–12357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8442757</ArticleId><ArticleId IdType="pubmed">34516349</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Qi Y., Teng X., Yang Z., Wei P., Zhang C., et al. Maturation mechanism of severe acute respiratory syndrome (SARS) coronavirus 3C-like proteinase. J Biol Chem. 2010;285:28134–28140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2934678</ArticleId><ArticleId IdType="pubmed">20489209</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng S.C., Chang G.G., Chou C.Y. Mutation of Glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease. Biophys J. 2010;98:1327–1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849084</ArticleId><ArticleId IdType="pubmed">20371333</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>